Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
/in Dendritic Cells, Glioblastoma, International PublicationsThe Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
/in Dendritic Cells, Glioblastoma, International PublicationsThe Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic CancerPhase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsMolecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
/in Dendritic Cells, Glioblastoma, International PublicationsComparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
/in Dendritic Cells, Glioblastoma, International PublicationsNewcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo
/in Glioblastoma, International Publications, Newcastle Disease VirusHigh-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion
/in Dendritic Cells, Glioblastoma, International PublicationsDendritic cell vaccines for high-grade gliomas
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer